Company intelligence / Profile preview
Evolve Biologics
- Ownership
- Private
- Development stage
- Phase 3
Overview
Evolve Biologics has completed Phase III clinical trials for its lead product, PlasmaCap IG (IVIG), and both IVIG and Albumin are in advanced stages of regulatory approval in the US and Canada. The company has secured multi-year supply commitments and significant investment to accelerate commercialization. Its proprietary PlasmaCap EBA™ technology enables higher yields of plasma proteins compared to traditional methods.
- Therapeutic areas
- ImmunologyRare Diseases
- Modalities
- Plasma-derived therapeutics (e.g., Intravenous Immunoglobulin (IVIG), Human Serum Albumin (HSA))
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Evolve Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Evolve Biologics.